MDXH.BR · MDxHealth SA

-

Please sign in to comment on MDXH.BR

1 Comment

Admin

4 years, 1 month ago

MDxHealth SA is currently in a long term uptrend where the price is trading 27.2% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.8.

Its net income has increased by 52.7% to $-14M since the same quarter in the previous year.

Finally, its free cash flow fell by 7.4% to $-5M since the same quarter in the previous year.

Based on the above factors, MDxHealth SA gets an overall score of 3/5.

Sector	Healthcare
Industry	Diagnostics & Research
CurrencyCode	EUR
ISIN	BE0003844611
Exchange	BR

Market Cap	86M
PE Ratio	None
Target Price	6.98
Beta	0.79
Dividend Yield	None

ABOUT

MDxHealth SA

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

MDXH.BR · MDxHealth SA

-

MDxHealth SA

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest MDxHealth SA using a moving average strategy